China
BioDlink Supports Junshi Biosciences in Achieving IND Approval for JS212, Its First Bispecific ADC
BioDlink congratulates Junshi Biosciences on receiving IND approval from China's NMPA for JS212, the company...
May 09, 2025 | News
China Grants Full Approval to Everest Medicines’ NEFECON® as First and Only Etiological Treatment for IgA Nephropathy
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...
May 07, 2025 | Regulatory
Beijing Tide Begins Phase II Trial of First-in-Class Non-Opioid CPSP Drug TRD205
Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class ...
May 06, 2025 | News
Fangzhou Launches Otsuka’s Iclusig® Online for Leukemia Care in China
Fangzhou Inc. , a leader in Internet healthcare solutions, announced the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhi...
May 06, 2025 | News
Nutshell Therapeutics Receives FDA IND Clearance for First-in-Human Trial of NTS071 Targeting p53 Y220C Mutation
Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical ...
May 05, 2025 | News
InnoCare’s Zurletrectinib Granted Priority Review in China for NTRK Fusion-Positive Solid Tumors
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that its new genera...
May 05, 2025 | News
JediCare, West China Hospital Complete First Human Study of Percutaneous Nodule Resection Device
JediCare Medical Technology Co., Ltd. a Shanghai, China based company ("the Company"), jointly with West China Hospital of Sichuan Univ...
May 02, 2025 | News
Innovent Biologics Doses First Patient in Global Phase 1 Trial of IBI3020, a First-in-Class Dual-Payload CEACAM5 ADC
Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment ...
April 30, 2025 | News
Keymed Biosciences Advances CDH17-Targeted ADC CM518D1 Into Phase I/II Trials for Solid Tumors in China
Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) develop...
April 28, 2025 | News
Innovent Biologics Secures NMPA Approval for Limertinib as First-Line Therapy for EGFR-Mutated NSCLC in China
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
April 28, 2025 | News
Doer Bio Begins Phase 2 Trial of Tri-Agonist DR10624 for MASLD and MASH Treatment
Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...
April 24, 2025 | News
Sichuan Kelun-Biotech Secures FDA IND Clearance for First-in-Class ADC SKB518
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new dru...
April 22, 2025 | News
Rona Therapeutics Secures IND Approval in China for siRNA-Based Hypertension Therapy RN1871
Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for&...
April 22, 2025 | News
China Rises as Global Force in Blood Purification Tech at BPPC Annual Conference
Blood Purification Professional Committee (BPPC) of the China Medical Device Industry Association (CMDIA) gathered in Liuyang, Hunan, for its annual c...
April 21, 2025 | News
Most Read
- Why Cell Therapy Systems Are Going Automatic: A New Era of Manufacturing
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2025
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Ravindra Rao Joins GOBI Technologies as Director of Life Sciences – APAC
- Amgen Announces $900 Million Expansion of Ohio Biomanufacturing Facility, Boosting Investment to Over $1.4 Billion
- Thermo Fisher Scientific Appoints Former CVS Health CEO Karen S. Lynch to Board of Directors
- Merck KGaA Reshapes Leadership for the Future with Key Executive Moves
- Aarian Health Appoints Thomas Keller as Business Director to Drive Innovation and Growth
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
News
